Midatech Pharma PLC Performance
The company secures a Beta (Market Risk) of 0.0, which conveys not very significant fluctuations relative to the market. the returns on MARKET and Midatech Pharma are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Midatech Pharma PLC has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable basic indicators, Midatech Pharma is not utilizing all of its potentials. The recent stock price agitation, may contribute to short-term losses for the retail investors. ...more
| Begin Period Cash Flow | 7.5 M | |
| Total Cashflows From Investing Activities | -278 K |
Midatech |
Midatech Pharma Relative Risk vs. Return Landscape
If you would invest (100.00) in Midatech Pharma PLC on November 10, 2025 and sell it today you would earn a total of 100.00 from holding Midatech Pharma PLC or generate -100.0% return on investment over 90 days. Midatech Pharma PLC is generating negative expected returns assuming volatility of 0.0% on return distribution over 90 days investment horizon. In other words, 0% of stocks are less volatile than Midatech, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Midatech Pharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Midatech Pharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Midatech Pharma PLC can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Midatech Pharma PLC is not yet fully synchronised with the market data | |
| Midatech Pharma PLC has some characteristics of a very speculative penny stock | |
| Midatech Pharma PLC has a very high chance of going through financial distress in the upcoming years | |
| The company reported the last year's revenue of 578 K. Reported Net Loss for the year was (5.46 M) with profit before taxes, overhead, and interest of 578 K. | |
| Midatech Pharma PLC has about 6.42 M in cash with (6.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.63. |
Midatech Pharma Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Midatech Stock often depends not only on the future outlook of the current and potential Midatech Pharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Midatech Pharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 3.2 M | |
| Cash And Short Term Investments | 10.1 M |
Midatech Pharma Fundamentals Growth
Midatech Stock prices reflect investors' perceptions of the future prospects and financial health of Midatech Pharma, and Midatech Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Midatech Stock performance.
| Return On Equity | -0.95 | |||
| Return On Asset | -0.52 | |||
| Operating Margin | (11.69) % | |||
| Current Valuation | (117.06 K) | |||
| Shares Outstanding | 6.93 M | |||
| Price To Earning | (1.02) X | |||
| Price To Book | 0.65 X | |||
| Price To Sales | 5.07 X | |||
| Revenue | 578 K | |||
| EBITDA | (5.66 M) | |||
| Cash And Equivalents | 6.42 M | |||
| Cash Per Share | 1.63 X | |||
| Debt To Equity | 0.1 % | |||
| Book Value Per Share | 1.90 X | |||
| Cash Flow From Operations | (6.01 M) | |||
| Earnings Per Share | (4.80) X | |||
| Total Asset | 12.91 M | |||
| Retained Earnings | (102.47 M) | |||
| Current Asset | 20.33 M | |||
| Current Liabilities | 9.1 M | |||
Things to note about Midatech Pharma PLC performance evaluation
Checking the ongoing alerts about Midatech Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Midatech Pharma PLC help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Midatech Pharma PLC is not yet fully synchronised with the market data | |
| Midatech Pharma PLC has some characteristics of a very speculative penny stock | |
| Midatech Pharma PLC has a very high chance of going through financial distress in the upcoming years | |
| The company reported the last year's revenue of 578 K. Reported Net Loss for the year was (5.46 M) with profit before taxes, overhead, and interest of 578 K. | |
| Midatech Pharma PLC has about 6.42 M in cash with (6.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.63. |
- Analyzing Midatech Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Midatech Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Midatech Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Midatech Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Midatech Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Midatech Pharma's stock. These opinions can provide insight into Midatech Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in poverty. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Other Consideration for investing in Midatech Stock
If you are still planning to invest in Midatech Pharma PLC check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Midatech Pharma's history and understand the potential risks before investing.
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |